Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19: FDA Anticipates Further Serology Test Development

Executive Summary

US FDA staff discussed hopes for additional serology and saliva tests for COVID-19, as well as at-home test options, during a 15 April webinar.

You may also be interested in...



COVID-19: FDA Warns Of Potential Risks Of Antibody Tests

The US agency’s decision to allow developers to distribute tests that detect COVID-19 in human blood without going through a clearance process has led to some misleading marketing, the agency warned in two recent statements.

It’s Raining EUAs: US FDA Drops Slew Of EUAs In Response To COVID-19

While US regulators have ramped up the number of authorizations they’ve granted to companies on an emergency basis in response to the COVID-19 crisis, they really kicked things into high gear in just the past few days. On 10 April the agency issued a record number of EUAs in response to the pandemic.

FDA Open To Home COVID-19 Testing With Caveats, OIVD’s Stenzel Says

The US FDA is open to the idea of home-testing for the COVID-19 virus, but only after making sure the test is completely safe and effective, and available only through a physician’s oversight, said Tim Stenzel, director of the agency’s Office of In Vitro Diagnostics and Radiological Health.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT126611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel